Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

ClinicalTrials.gov ID: NCT00103506

Public ClinicalTrials.gov record NCT00103506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.

Study identification

NCT ID
NCT00103506
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
646 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2004
Primary completion
Apr 30, 2014
Completion
May 31, 2014
Last update posted
Oct 18, 2015

2004 – 2014

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Not listed Alabaster Alabama
Not listed Surprise Arizona
Not listed Berkeley California
Not listed Loma Linda California
Not listed Los Angeles California
Not listed Sacramento California
Not listed Norwalk Connecticut
Not listed Stamford Connecticut
Not listed Jacksonville Florida
Not listed Miami Florida
Not listed Stuart Florida
Not listed West Palm Beach Florida
Not listed Altanta Georgia
Not listed Boise Idaho
Not listed Indianapolis Indiana
Not listed Lexington Kentucky
Not listed Metairie Louisiana
Not listed New Orleans Louisiana
Not listed Minneapolis Minnesota
Not listed Hackensack New Jersey
Not listed Chapel Hill North Carolina
Not listed Charlotte North Carolina
Not listed Durham North Carolina
Not listed Portland Oregon
Not listed Philadelphia Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed North Charleston South Carolina
Not listed Nashville Tennessee

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00103506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 18, 2015 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00103506 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →